Pulse Biosciences (NASDAQ:PLSE) Upgraded to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Pulse Biosciences from “sell” to “hold,” while the broader analyst consensus remains “Moderate Buy,” with four buy ratings and one sell rating and an average target price of $45.25.
• Shares opened at $53.24 after recently trading down 2.7%, near the 12-month high of $55.37. The company’s latest quarterly results missed expectations, reporting an adjusted loss of $0.36 per share and revenue of $0.43 million.
• Insiders and institutional investors have shown strong interest: insiders own 74% of the stock and purchased shares recently, while institutional ownership stands at 76.95%, including new positions from BlackRock and Bank of America.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Sunday, Wall Street Zen reports.

PLSE has been the topic of a number of other reports. Oppenheimer reiterated an "outperform" rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Weiss Ratings restated a "sell (d-)" rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Mizuho set a $45.00 price target on shares of Pulse Biosciences in a research report on Monday, August 10th. Canaccord Genuity Group increased their price objective on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Finally, Needham & Company LLC assumed coverage on shares of Pulse Biosciences in a research report on Monday, August 17th. They issued a "buy" rating and a $58.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $45.25.

Pulse Biosciences Trading Down 2.7%

Shares of Pulse Biosciences stock opened at $53.24 on Friday. The business's 50 day simple moving average is $37.97 and its 200-day simple moving average is $28.00. The stock has a market capitalization of $3.68 billion, a price-to-earnings ratio of -45.12 and a beta of 1.63. Pulse Biosciences has a twelve month low of $12.56 and a twelve month high of $55.37.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The company had revenue of $0.43 million during the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. Sell-side analysts predict that Pulse Biosciences will post -1.29 earnings per share for the current year.

Insider Buying and Selling

In other Pulse Biosciences news, COO Liane Teplitsky bought 1,001 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were purchased at an average cost of $49.95 per share, for a total transaction of $49,999.95. Following the transaction, the chief operating officer directly owned 4,095 shares in the company, valued at $204,545.25. The trade was a 32.35% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders purchased 4,095 shares of company stock valued at $199,931. 74.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of PLSE. BlackRock Inc. acquired a new position in shares of Pulse Biosciences during the second quarter valued at $40,672,000. Bank of America Corp DE acquired a new stake in Pulse Biosciences in the second quarter worth about $40,115,000. California State Teachers Retirement System lifted its holdings in Pulse Biosciences by 2,600.0% in the second quarter. California State Teachers Retirement System now owns 567,883 shares of the company's stock worth $15,747,000 after purchasing an additional 546,850 shares during the period. Portolan Capital Management LLC acquired a new stake in Pulse Biosciences in the third quarter worth about $1,809,000. Finally, Brooklyn Investment Group grew its position in Pulse Biosciences by 330.7% in the 4th quarter. Brooklyn Investment Group now owns 130,340 shares of the company's stock valued at $1,844,000 after buying an additional 100,081 shares in the last quarter. Institutional investors own 76.95% of the company's stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source